CA3114149C - Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same - Google Patents

Abstract

The present invention provides an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide, as well as a pharmaceutical composition comprising said immunity-inducing agent.

Description

[0001] The present invention relates to a novel immunity-inducing agent for inducing antigenic peptide-specific immune responses and comprising an antigenic peptide-adjuvant nucleotide conjugate, and a pharmaceutical composition comprising the same. BACKGROUND ART-

[0002] The basic principle for the prevention of infection through vaccination is that pseudo-infection is artificially established to induce acquired immunity and to elicit antibody production and cell-mediated immunity against particular pathogens. It is known that in acquired immunity, T and B cells, which are responsible for “memory” in immunity, play key roles, and the diversity of antibody variable regions caused by DNA recombination enables specific immune responses to numerous numbers of antigens. In contrast, innate immunity, which is mainly mediated by phargocytes such as leukocytes, macrophages and dendritic cells, has been conventionally considered to be a non-specific process of phagocytosis of foreign substances and pathogens, and to merely serve as a “stopgap measure” until acquired immunity is established. However, as a result of advances in studies on the molecular mechanisms of innate immunity, it has been clarified that self/nonself-specific recognition takes place also in innate immunity, and that innate immunity is essential for the establishment of acquired immunity. To be more specific, it has been clarified in recent studies that a family of Toll-like receptors (TLRs), present on antigenpresenting cells such as dendritic cells, macrophages and B cells, can respond to various pathogens, induce cytokine production, and induce acquired immunity through, for example, promotion of differentiation of naive T cells into Thl cells, and activation of killer T cells.

[0003] Pathogens recognized by the series of TLRs are composed of a wide variety of Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -2- constituents. One of those constituents is a DNA having a CpG motif (CpG DNA), which acts as a ligand for TLR9. A CpG motif is a nucleotide sequence composed of six nucleotides, in which cytosine (C) and guanine (G) are situated side-by-side at the center and flanked by two purine nucleotides and two pyrimidine nucleotides, and are represented by -PuPu-CG-PyPy- (Pu represents a purine nucleotide, and Py represents a pyrimidine nucleotide) (in humans, GTCGTT is also known to have ligand activity for TLR9). This motif is rarely found in mammals, and is found commonly in bacteria (based on frequency as calculated in terms of probability). In mammals, most of rare CpG motifs are methylated. Unmethylated CpG motifs, which are rarely observed in mammals, have potent immunostimulatory activity (refer to e.g., NPLs 1 to 3). CpG DNA incorporated into cells by endocytosis is recognized by TLR9 present in phagosome-like vesicles, and can induce strong Thl responses. Thl responses suppress Th2-dominated allergic responses, and also have potent antitumor activity. Therefore, CpG DNA is expected to be used not only for infection prevention but also as an adjuvant for allergic and neoplastic diseases (refer to e.g., NPL 4).

[0004] However, when CpG DNA is used as an adjuvant in immunotherapy, the problem is how to deliver CpG DNA into target cells while protecting DNA against degradation by nucleases in cytoplasm or plasma, or against non-specific binding to proteins.

[0005] The present inventors have focused their attention on polysaccharides having a P-l,3-glucan backbone (hereinafter also abbreviated as “P-1,3-glucans”) as a novel gene carrier, and found that P-l,3-glucans are capable of forming new types of complexes by binding to various nucleic acids including nucleic acid drugs (e.g., antisense DNA, CpG DNA) (refer to e.g., PTLs 1, 2, and NPLs 5 to 7).

[0006] It was found that when P-1,3-glucan naturally existing in a triple helix conformation is dissolved in an aprotic polar organic solvent such as dimethyl sulfoxide (DMSO) or in a 0.1 N or higher alkali solution to allow glucan to be cleaved into single strands, then a single¬ strand nucleic acid is added, and the solvent is replaced with water or neutralized again, a triple helix complex consisting of one nucleic acid molecule and two P-1,3-glucan molecules Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -3- is formed. It is considered that in such a triple helix complex, a linkage between the P-1,3-glucan molecules and the nucleic acid molecule is mainly formed by hydrogen bonding and hydrophobic interaction (refer to NPL 8).

[0007] The complexation of nucleic acids with P-1,3-glucans, as described above, enabled delivery of nucleic acids into cells while suppressing undesired interactions of nucleic acids with proteins in the body, such as hydrolysis of nucleic acids by nucleases, or non-specific binding of nucleic acids to plasma proteins. The delivery of CpG DNA into cells was succeeded with the use of a complex of P-l,3-glucan and DNA, or a ternary complex containing a protein with antigenicity (refer to e.g., PTLs 3, 4, and NPLs 9 to 11).

[0008] However, the aforementioned conventional techniques had some problems as described below. For example, according to the method of producing a P-l,3-glucan/antigenic protein/CpG DNA ternary complex as disclosed in NPL 11, a formyl group is produced on a glucose residue at the side chain of P-1,3-glucan by oxidization with periodic acid, and the formyl group is reacted with an amino group of a peptide with antigenicity (hereinafter also abbreviated as “antigenic peptide”) by reductive amination reaction, so that a complex in which P-1,3-glucan and the antigenic peptide are covalently bound together can be formed. However, this method has a problem of very low yield. In view of such circumstances, according to, for example, the method of producing a P-l,3-glucan/antigenic protein (antigenic peptide)/CpG DNA ternary complex as disclosed in PTL 4, P-l,3-glucan having a formyl group at the side chain thereof and an antigenic peptide are reacted with each other in an aqueous alkaline solution at the same time as, or sequentially followed by, neutralization, so that improvement can be achieved in yield and the reactivity between the formyl group at the side chain of P-1,3-glucan and an amino group of the antigenic peptide. However, since a peptide contains a plurality of amino groups, control of a reaction site is difficult to achieve. Therefore, there is concern that there may occur various problems, such as variation in immunogenicity depending on the reaction site of an antigenic peptide, or difficulty in separation and purification due to complexity of reaction mixtures with P-l,3-glucan. Further, the procedure for forming a Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -4- P-l,3-glucan/antigenic peptide complex based on the formation of covalent bonding is more complicated than that for forming a P-l,3-glucan/DNA complex through hydrogen bonding. From these viewpoints, the method of producing a P-l,3-glucan/antigenic peptide/CpG DNA ternary complex as disclosed in PTL 4 still has problems with ease of production and the like.

[0009] In view of such problems, the present inventors have proposed a peptide/p-1,3-glucan complex having excellent ease of production and high immunostimulatory activity, the complex comprising: a polysaccharide having a P-l,3-glucan backbone; and a peptide/polynucleotide conjugate in which an antigenic peptide is covalently bound to a polynucleotide or polynucleotide derivative, wherein the polynucleotide or polynucleotide derivative of the peptide/polynucleotide conjugate is bound via hydrogen bonding to the polysaccharide having a P-1,3-glucan backbone to form a complex having a triple helix structure consisting of one molecular chain of the polynucleotide or polynucleotide derivative and two molecular chains of the polysaccharide having a P-l,3-glucan backbone (refer to PTL 5). However, PTL 5 is silent about whether the peptide/polynucleotide conjugate, which constitutes the peptide/p-1,3-glucan complex, has per se immunity induction activity.

[0010] There are some reports suggestive of the immunity induction activity of conjugates of CpG DNA with antigenic peptides or proteins (refer to NPLs 12, 13). NPL 12 discloses that administration of conjugates of CpG DNA with ovalbumin (OVA) antigen-derived 18- to 24-mer peptides improves OVA antigen presentation in CD8+ T lymphocytes (CTLs), but is not explicitly demonstrative of induction of CTL cytotoxic activity. NPL 13 discloses that administration of conjugates of CpG DNA with OVA antigen proteins induces CTL cytotoxic activity, but those conjugates were injected at a high dose of 10 pg per mouse, and also, production of those conjugates required complicated steps of chemical DNA synthesis, production of antigen proteins through culturing/purification, and conjugation of DNA with antigen proteins. Thus, the technique of NPL 13 has problems with activity at low doses and ease of production CITATION LIST Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -5- PATENT LITERATURES

[0011] PTL 1: International Patent Publication No. WO 01/34207 PTL 2: International Patent Publication No. WO 02/072152 PTL 3: Japanese Unexamined Patent Application Publication No. JP 2010-174107 PTL 4: Japanese Unexamined Patent Application Publication No. JP 2007-70307 PTL 5: International Patent Publication No. WO 2015/118789 NON PATENT LITERATURES

[0012] NPL 1: Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger. H. Wagner, Adv. Immunol., 13, 329-368 (1999). NPL 2: CpG Motifs in Bacterial DNA and Their Immune Effects. M. Krieg, Annu. Rev. Immunol., 20, 709-760 (2002). NPL 3: The Discovery of Immunostimulatory DNA Sequence. S. Yamamoto, T. Yamamoto, and T. Tokunaga, Springer Seminars in Immunopathology, 22, 11-19 (2000). NPL 4: Standard Immunology, 2nd Edition, Igaku-Shoin Ltd., 333 (2002) NPL 5: Molecular Recognition of Adenine, Cytosine, and Uracil in a SingleStranded RNA by a Natural Polysaccharide: Schizophyllan. K. Sakurai and S. Shinkai, J. Am. Chern. Soc., 122, 4520-4521 (2000). NPL 6: Polysaccharide-Polynucleotide Complexes. 2. Complementary Polynucleotide Mimic Behavior of the Natural Polysaccharide Schizophyllan in the Macromolecular Complex with Single-Stranded RNA and DNA. K. Sakurai, M. Mizu and S. Shinkai, Biomacromolecules, 2, 641-650 (2001). NPL 7: Dectin-1 Targeting Delivery of TNF-a Antisense ODNs Complexed with P-l,3-glucan Protects Mice from LPS-induced Hepatitis. S. Mochizuki and K. Sakurai, J. Control. Release, 151, 155-161 (2011). NPL 8: Structural Analysis of the Curdlan/Poly(cytidylic acid) Complex with Semiempirical Molecular Orbital Calculations. K. Miyoshi, K. Uezu, K. Sakurai and S. Shinkai, Biomacromolecules, 6, 1540-1546 (2005). NPL 9: A Polysaccharide Carrier for Immunostimulatory CpG DNAs to Enhance Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -6- Cytokine Secretion. M. Mizu, K. Koumoto, T. Anada, T. Matsumoto, M. Numata, S. Shinkai, T. Nagasaki andK. Sakurai, J. Am. Chern. Soc., 126, 8372-8373 (2004). NPL 10: Protection of Polynucleotides against Nuclease-mediated Hydrolysis by Complexation with Schizophyllan. M. Mizu, K. Koumoto, T. Kimura, K. Sakurai and S. Shinkai, Biomaterials, 25, 15, 3109-3116 (2004). NPL 11: Synthesis and in Vitro Characterization of Antigen-Conjugated Polysaccharide as a CpG DNA Carrier. N. Shimada, K. J. Ishii, Y. Takeda, C. Coban, Y. Torii, S. Shinkai, S. Akira andK. Sakurai, Bioconjugate Chern., 17 1136-1140 (2006). NPL 12: Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells, Khan S., et al., J. Biol. Chern., 282, 21145-21159 (2007). NPL 13: Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity, Kramer K,. et al., Mol. Ther., 25, 62-70 (2017). SUMMARY OF INVENTION TECHNICAL PROBLEM

[0013] It was not known whether peptide/polynucleotide conjugates have apparent immunity induction activity on their own.

[0014] The present inventors found that peptide/polynucleotide conjugates which are not complexed with [3-1,3-glucan, especially peptide/polynucleotide conjugates comprising a CpG motif, have high immunity induction activity on their own; and thus, the inventors completed the present invention. Therefore, this invention has as its object to provide an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, and a pharmaceutical composition comprising the same. SOLUTION TO PROBLEM

[0015] A first aspect of the present invention in accordance with the aforementioned object solves the problems mentioned hereinabove by providing an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single¬ chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -7 - peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide.

[0016] In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide may have an amino acid length of not less than 5 but not more than 30.

[0017] In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide may have an amino acid length of not less than 8 but not more than 11.

[0018] In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs.

[0019] In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may have a nucleotide length of not less than 15 but not more than 40.

[0020] In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may have a nucleotide length of not less than 20 but not more than 30.

[0021] In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may be a polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds.

[0022] In the immunity-inducing agent according to the first aspect of the present invention, in the polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, not less than 50% of the phosphodiester bonds may be substituted with phosphorothioate bonds.

[0023] In the polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, not less than 90% of the phosphodiester bonds may be substituted with phosphorothioate bonds.

[0024] In the immunity-inducing agent according to the first aspect of the present invention, one or both of the covalent bond between the spacer and the polynucleotide or polynucleotide Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 derivative, and the covalent bond between the spacer and the antigenic peptide are preferably a covalent bond(s) that is(are) cleavable in biological environment.

[0025] In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide which constitutes the polynucleotide/peptide conjugate, and the spacer bound to the polynucleotide or polynucleotide derivative may be bound together via a covalent bond (disulfide bond) produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer.

[0026] In the immunity-inducing agent according to the first aspect of the present invention, the spacer may comprise a repeating unit represented by the following formula. [0027] [Chern. 1] X II P-X-R— i Xl jn

[0028] In the above formula, X represents an oxygen atom or a sulfur atom (wherein each X may be the same or different), R represents any of (CH2)PO, (CH2)qNH, and (CH2CH2O)m (wherein m, p and q each independently represent a natural number of not more than 10), and n represents a natural number of not more than 10.

[0029] In the immunity-inducing agent according to the first aspect of the present invention, the spacer may have a structure represented by any of the following formulas. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -9- [0030] [Chern. 2] 0 P“O~(CH2)6— NHo o ^o-(ch2)2—nh-Mch^—s— oO ° ° P-O—(CH2)6~”NH— O—(CH2)2— NH— (CH2)2—S— S' O O P-O-(CH2)6—NH-U—(CH2)2—s— O' o o P-Q—(CH2)6— NH— (CH2)2—S So o o P-O-(CH2)6—NH^^—(CH2)5—NH-L(CH2)2—s— 6- o o o P-O-(CH2)6—NH-LfCH^—NH— (CH2)2“S— S’ P-O-(CH2)6—NH-^O-fCH^—NH-JJ—(CH2)5—NH-L^ch^—S— oO O 0 0 P-O-(CH2)6—NH-^O-fCHaJs—NH-11—(CH2)5—NH-U-tCH^—S— s-

[0031] In the immunity-inducing agent according to the first aspect of the present invention, it is preferred that the antigenic peptide should have an amino acid length of not less than 5 but not more than 30, that the polynucleotide or polynucleotide derivative should be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs, that the polynucleotide derivative should be a polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, and that one or both of the covalent bond between the spacer and the polynucleotide or Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 10- polynucleotide derivative, and the covalent bond between the spacer and the antigenic peptide have a structure(s) that is(are) a covalent bond(s) that is(are) cleavable in biological environment.

[0032] In the immunity-inducing agent according to the first aspect of the present invention, it is more preferred that the antigenic peptide should have an amino acid length of not less than 8 but not more than 11, that the polynucleotide or polynucleotide derivative should be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs and having a nucleotide length of not less than 20 but not more than 30, that the polynucleotide derivative should be a polynucleotide derivative in which not less than 90% of phosphodiester bonds are substituted with phosphorothioate bonds, that the antigenic peptide which constitutes the polynucleotide/peptide conjugate, and the spacer bound to the polynucleotide or polynucleotide derivative should be bound together via a covalent bond (disulfide bond) produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer, and [0033] that the spacer should have a structure represented by any of the following formulas. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 11 - [0034] [Chem. 3] OP-O-(CH2)6—NH-U-O-(CH2)2— O NH~L(CH2)2— ° S— 6" OP~O—(CH2)6—NH—° O—(CH2)2—NH— (CH2)2—S— S' O O P-O—(CH2)6—NH— —(CH^—'S™' 6' o o -P-O—(CH2)6—NH— (CH2)2—S S' O OO P-O-(CH2)6—NH— (CH2)5“NH-~L(ch2)2—s— 6- o o o P-O-(CH2)6—NH-IJ—(CH2)5—NH-lL(CH2)2—s— S' O O 0 0 P-O-(CH2)6—NH“^-O“(CH2)2—NH-1^—(CH2)5—NH-^—(CH^—S— oo o o o P-O-(CH2)6—NH^~O~(CH2)2—NH-L(CH2)5-”NH-^(CH2)2—s— S'

[0035] In the immunity-inducing agent according to the first aspect of the present invention, a substance having immunostimulatory activity may be further contained as an adjuvant.

[0036] A second aspect of the present invention solves the problems mentioned hereinabove by providing a pharmaceutical composition comprising the immunity-inducing agent according to the first aspect of the present invention.

[0037] The second aspect of the present invention may be a pharmaceutical composition for treating tumor. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 12-

[0038] According to another aspect of the present invention, there is provided a method for treating or preventing a disease, the method comprising administering an effective amount of the immunity-inducing agent according to the first aspect of this invention to a subject in need thereof. In this aspect, the disease may be a tumor.

[0039] According to a still another aspect of the present invention, there is provided use of the immunity-inducing agent according to the first aspect of this invention for the production of a medicament for treating or preventing a disease. In this aspect, the disease may be a tumor. ADVANTAGEOUS EFFECTS OF INVENTION

[0040] The peptide/polynucleotide conjugate of the present invention can be used as a highly active immunity-inducing agent having excellent ease of production. Further, immunity-inducing agents having immunity induction activity against a wide variety of antigens can be easily designed by combining an antigenic peptide with a polynucleotide or polynucleotide derivative in an appropriate manner. BRIEF DESCRIPTION OF DRAWINGS [0041] [FIG. 1] FIG. 1 depicts the results of the flow cytometric analysis performed in Example 2. [FIG. 2] FIG. 2 depicts the results of the flow cytometric analysis performed in Example 3. [FIG. 3] FIG. 3 depicts the results of the flow cytometric analysis performed in Example 4. [FIG. 4] FIG. 4 depicts the results of the flow cytometric analysis performed in Example 4. [FIG. 5] FIG. 5 depicts the results of the flow cytometric analysis performed in Example 5. [FIG. 6] FIG. 6 depicts the results of the flow cytometric analysis performed in Example 7. [FIG. 7] FIG. 7 depicts the results of the flow cytometric analysis performed in Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 13 - Example 7. DESCRIPTION OF EMBODIMENTS

[0042] The immunity-inducing agent according to the first aspect of the present invention (hereinafter also abbreviated as “immunity-inducing agent”) comprises, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide.

[0043] The peptide/polynucleotide conjugate is a complex in which an antigenic peptide and a polynucleotide or polynucleotide derivative are bound together via covalent bonding. As the “antigenic peptide”, any peptide having any amino acid sequence consisting of any numbers of amino acid residues can be used without particular limitation, as long as it has antigenicity — namely as long as it can be recognized as a foreign substance in the immune system of a living body and elicit specific antibody production (induce an immune response). In this aspect of the present invention, if an antigenic peptide has no cysteine (Cys) in its sequence, a peptide modified by artificially adding one cysteine to the N-terminus of an antigenic epitope peptide derived from an antigenic protein can be used as an antigenic peptide. Examples of the antigenic peptide used to produce the peptide/polynucleotide conjugate serving as an active component of the immunity-inducing agent according to this aspect of the invention include proteins responsible for allergies such as food allergy, pathogens such as bacteria and viruses, and proteins originating from tumor cells and the like, as long as they have a partial amino acid sequence that can act as an epitope. The number of amino acid residues constituting the antigenic peptide is not particularly limited as long as they can act as an epitope, but the number of amino acid residues is commonly in the range of from 5 to 30, and most commonly in the range of approximately from 8 to 17.

[0044] The antigenic peptide can be obtained using any known method, such as enzymatic degradation of a protein of origin, or peptide synthesis. Further, the amino acid sequence of Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 14- the antigenic peptide can be determined using any known method such as epitope analysis with peptide arrays.

[0045] Examples of peptides that can be used as antigenic peptides include: MHC-1 T cell epitopes registered on the epitope peptide database IEDB (www.iedb.org; last accessed: 08/11/2014); the peptides disclosed in the paper written by Chowell, et al. (TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes, PNAS, April 7, 2015, 112 (14), E1754-E1762, Table. SI); and the peptides listed in Tables 1 to 7 below. In this aspect of the present invention, peptides modified by adding one cysteine residue to the N-terminus of such antigenic peptides (except for those antigenic peptides inherently having a cysteine residue in their sequence) can be used as antigenic peptides. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 15- [0046] [Table 1] Diseases to be treated: Infections Antigen Sequence MHO subtype SEQ ID NO. HumanPapilloma virus (HPV) E7 ®DLQPiTT HLA-A’0201 1 RAHYNIV1F H-2Db 2 HPVEB NTLEQTVKK HLA-A’1101 3 EVYDFAFRDL H-2 Kb 4 HepatiteB virus (HBV) S protein FLLTRILTI HLA-A‘0201 I GLSP1VWI.SV HlA-A-0201 B WLSLLVPFV HLA-A‘0201 7 HBV comprotein FLPSDFFPSV HLA-A‘O201 8 YVNVNMGLK HLA-A-11 9 HBVpdymMUM KLHLYSHPI HLA-A‘0201 W GLSRYVARL HLA-A‘0201 11 HBV polyprotoin KLVALGINAV HLA-A’0201 12 GVDPNIRTGV HLA-A’0201 13 ALYDWTKL Hl-A A‘0201 14 HBVHBeAfl VWLSVIWM H-2 Kb 15 Herpee aknptex vims (HSV) (pycoprotolnO SLPITVYYA HLA-A‘0201 16 VLLNAPSEA HLA-A‘0201 17 ALLEDPVGT HLAA‘0201 18 HSV glycoprotein B RMI GDVMAV HLA-A‘0201 1» NI.LTTPKFT HLAA‘0201 20 Cytomegalovirus (CMV) pp85 NLVPMVATV HLA-A‘0201 21 VYALPLKML HLA-A‘2402 22 QYDPVAALF HIAA‘2402 23 CMVIE4 VLEEFSVML HLA-A‘0201 24 AYAQKirKI HLA-A‘2402 25 Influenza tfrut NP CFLLKLSDY HLA-A*m01 26 Influenza virus Ml GILGFVF1L HLAA‘0201 27 ILGFVFTLTV HLA-A‘0201 28 Influenza vlrw HA2 YIGEVl.VSV HLA-A'0201 29 influenza virus nucleoprotein KLGLFYNQMM HLA-A‘0201 30 Respiratory Syncytial Virus (RSV) M2 YLEKESIW HLA^*0101 31 SY1GSINN1 H-2 Kd 32 RSVNP KMt KEMGEV HLA-A‘0201 33 RSVP protein AITIILAAV HLA-A‘0201 34 ALLSTNKAV HLA-A‘0201 36 Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 16- [0047] [Table 2] Diseases to be treated: Infections Antigen Sequence MHC subtype SEQ ID NO. ELDKYKNAV HLA-A*0201 ae FLLGVGSAI HLAA‘0201 37 FMNYTLNNI HLAA'0201 38 HLLGEVNKI HLAAW1 39 KIMTSKTDV HLA-A-0201 40 KINQSLAFl HLA-A‘0201 41 SVYDFFVWL H-2Kb 42 HumanImmunodeficiency Virus <HIV> Ew RYLKDQQLL HLAA‘2402 43 SII NATAIAV HL A A‘0201 44 HIV Gag SLYNTVATI HLAA'0201 48 RILNAWVKV HLAA’0201 46 FLGKIWPS HLA-A’0201 47 TLNAVWKW HLA-A-0201 48 SLFNWATL HLA-A-0201 49 SLYNWATLY HLA,A*0201 SO RnlyomiwiniBVPi LLIWBWW HLAA‘0201 61 fWimavfcwLarge T LLLIWFRPV HI A A‘0201 62 HumanT-oeNleukemia virus type 1 (HTLV-1>T« LLf GYPVYV HLA A’0201 63 SFHSLHLLF HLAA’2402 54 Epeteh-Biwr virus (EBV) BRLF1 DYCNVLNKF F HLA A’2402 66 Tl DYKPLSV Hl A-A-0201 66 YVLDHLIW HLA-A-0201 67 tSVLMP-1 YHFMLWRL Hl A A‘0201 68 YLQQNWWTL HLA-A*0201 69 Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 17- [0048] [Table 3] Diseases to be treated: Cancers Antigen Sequence MHC subtype SEQ ID NO. ABL1 QQAHCLWCV HLA-roaii ®0 ACPP ALDVYNGLL HLAA’0201 ei ACPP ALNVYNGLL HLA-A‘02(W 62 awe NLFETPVEA HLA-A‘0201 63 BW GLQHWVPEL HLA-A‘0201 64 BAP31 KI DVGNAEV HLA-A-0201 66 BCL-2 PLFDFSWLSL HLA-A-0201 66 YLNRHLH7WI HL.A-A’0201 67 BCL-2 WLSLKILLSL Hl.A-A-0201 66 BCL-2 ALSPVPPW HLAA’0201 69 BCK YLNDHLEPWI HLA-A‘0201 70 wll CLPSPSTPV HLA-A‘0201 71 BMW TLQDIVYKL HLA-A‘0201 72 CAMB. MLMAQEALAFL HtAA‘0201 73 CB9L2 ALYLMELTM HLA-A’0201 74 cm YLISGDSPV HLA-A‘0201 7« CEACAM YLSGANLNL HI A-A‘0201 76 DUC1 ILGVL1SLV HLA-A’0201 77 (ndoelaNn LLVPTCVFLV HLA-A‘0201 73 EphA2 TLADFDPRV HLA-A‘0201 79 ea« YMCSFLFNL HLA-A‘0201 60 EZH2 SQADALKYV HLA-A‘0201 81 FAPa ALVCYGPGI HLA-A‘0201 82 FAPa GLFKCGIAV HLA-A‘0201 83 FLT1 TLFWLLTL HLA-A’0201 84 FOLR1 EIWTHSYKV HLA-A‘0201 86 Glydpan3 FVGEFFTDV HLA-A‘0201 86 gpioo KTWGQYWOV HLA-A‘0201 87 «*<» ITDQVPFSV HLA-A‘0201 86 gpioo IMDQVPFSV HLA-A‘0201 89 gpioo YLEPGPVTV HLA-A‘0201 90 HO-1 QLFEELGEL HLA-A‘0201 91 Heparanaw LLLGPLGPt HI A-A‘0201 92 HER2 ItHOGAYSL HLA-A’0201 93 HER2 LIAHNQVRQV HLA-A‘0201 94 Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 18- [0049] [Table 4] Diseases to be treated: Cancers Antigen Sequence MHC subtype SEQ ID ’ NO. HEW K1FGSLAFL HLA-A‘02(M 95 HMMR ILSLFLMKL HLA-A‘0201 95 IL13Ra ALPFGFILV HLA-A-0201 97 IDO ALLEIASCL HLA-A*0201 98 ITGB8 ALMEQQHYV Hl A A*0201 99 KLK VISNDVCAQV HLA-A’0201 100 Lengoin FIYDFCIFGV HLA-A-0201 101 LIVW QLCPICRAPV HLAA*02Q1 102 LMP-1 YLQQNWWn HLA-A'0201 103 LY0K LLLAStAAGL HLA-A‘O201 104 MAGE-10 GLYDGMEHL HLA-A‘0201 105 MAGE-A3 KVAELVHFL HLA-A‘0201 105 MAGE-CI FLAMLKNTV HLA-A‘0201 107 MAGE-3 FLWGPRAI.V HLA-A‘0201 108 MAGE-4 GVYDGREHTV HLA-A‘0201 109 MAGE-A1 KVLEYVIKV HLA-A’0201 110 MAGE-A2 YLQLVFGIEV HL A A‘0201 111 MART-1 ELAGIGILTV HLAA‘0201 112 M3LN SLL Fl.LFSL HLA-A‘0201 113 MSLN VLPLTVAFV HLA-A‘0201 114 MKSdM AQCQETIRV HLA-A‘0201 115 MS4A1 Sl.Fl.GII.SV HLA-A‘0201 116 NRP-1 GMLGMVSGL HLA-A‘0201 117 NY-E8O-1 SLLMWITQC HLA-A‘0201 118 ^WiMBSO-1 SLLMWITQV HLA-A‘0201 119 BGLAP YLYQWLGAPV HLA-A‘0201 120 P53 YLGSYGFRI. HLA-A‘0201 121 p53 KLCPVQLWV HLA-A‘0201 122 p53 SLPPPGTRV HLAA‘0201 123 p53 GLAPPQHLIRV HLA-A‘0201 124 p53 LLGRNSFEV HLA-A‘0201 125 P53 RMPEAAPPV HLA-A‘0201 126 P53 STPPPGTRV HLA-A’0201 127 PASO1 YLVGNVCIt. HLA-A‘0201 128 PASD1 QLLDGFMITL HLA-A‘0201 129 Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 - 19- [0050] [Table 5] Diseases to be treated: Cancers Antigen Sequence MHC subtype SEQ ID NO. PASD1 ELSDSLGPV HLA-A-0201 130 PLAC1 SIDWFMVTV HLA-A-0201 131 Prl VLQEINVTV HLA-A*0201 132 FRAME ALYVDSLFFL HLA-A-0201 133 FRAME VLDGLDVLL HLA-A’0201 134 MOTonm YLQWIEFSI HLA-A-0201 135 JPSA KLQCVDLHV HLA-A*0201 135 PSA FLTPKKLQCV HLA-A-0201 137 PSCA AILALLPAL HLA-A*0201 138 PSCA QLGEQCWTV HLA-A‘0201 13© neilA rwwIR SLFEPPPPG HLA-A‘0201 140 PSMA MMNDQLMFL HLA-A‘0201 141 PSMA VLAGGFFLL HLA-A‘0201 142 RNF43 ALWPWLLMAT HLA-A’0201 143 SARTO RLAEYQAYI HLA-A’0201 144 SW1 MLAVFLPIV HLA-A‘0201 145 oyrvivin LMLGEFLKL HLA-A-0201 146 SurvMn-3a LTLGEFl KL HLA-A’0201 147 Survtvin HPPAWQPFL HLA A‘0201 148 TACE YLIELIDRV HLA-A‘0201 149 tarpan FLPSPLFFFL HLA-A‘0201 150 TARP Fl Fl RNFSL HLA-A-0201 151 TetomraM YLQVNSLQTV HLA-A‘0201 152 retowwase ILAKFLHWL HLA-A’0201 153 TotonMmMB ALLTSRLRFi HLA-A’0201 154 Tatonwraae RLTSRVKAL HLAA-0201 155 Teiomwrase GLLGASVLGl HLA-A’0201 156 TGFf RLSSCVPVA HLA-A’0201 157 toptt FLYDDNQRV HLA-A‘0201 158 TRAG GL1QLVEGV HLA-A‘0201 159 TRAG S1LLRDAGLV HLA-A’0201 160 Mik* LLLTVLTW HLA A-0201 161 Mucin LLLLTVLTV HLA-A’0201 162 Tyrosinase YMDGTMSQV HLAA’0201 163 WH RMFPNAPYL HLA-A‘0201 164 Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -20- [0051] [Table 6] Diseases to be treated: Cancers Antigen Sequence MHC subtype SEQ ID NO. W1 VLDFAPPGA HU-A’0^1 18® wri SLGGQQYSV HLA-A‘0201 168 ABU CLWCVPQLR HLA-A'0201 167 3CR-ABL GVRGRVEFI HLAA‘0201 168 HSP105 RLMNDMTAV HLA-A‘0201 16» HSP105 KLMSSNS7DL HLA-A‘0201 170 CO105 l.LIAALWYV HLA-A’0201 171 3CL-2A1 DYLOYVLQ1 HLA-A-24Q2 172 ClorfW GYCTQIGIF HlA-A-2402 173 Cwbonlc onhydrMB EYRALQI HL HLA A-2A02 174 0EPDC1 LYYFLFVNI HLA-A’2402 17« FOXM1 lYlWItDHF HLA-A‘2402 178 0^dpM3 FYlLSLttL HLA-A’2402 177 >100 VYFFLPDHL HLA-A‘2402 178 HJURP KWI ISPVKI HLA-A*2402 17« hTOMMp KLRGEVKQNL HLA-A‘2402 180 IL13r VYYNWQYLL HI A-A-2402 181 KIF20A KYYLRVRPlI HLA A-2402 182 KIF20A VYl.RVRPLL HLAA-2402 183 LY6K RYCNLEGPP1 HLA-A’2402 184 MELK F.YGPGGNLF Hl A-A’2402 186 Midkine RYNAQCQE1I HLA.A’2402 186 Nul2 VYGIRl EHF HLA-A-2402 187 BGLAP LYQWLGAPV HLA-A-2402 188 p-Cadherin DY1NFWGSR1 HLAA-2402 188 PSA CYASGWGSI HLA-A‘2402 180 RNF43 NYQPVWLCL Hl A A-2402 181 Survlvin AYACNTSTL HLA-A‘2402 182 rm SYRNFIAYL HLA A-2402 183 lynMraw AFLPWHRLF HI.A A'2402 184 WT1 CY1WNQMNI Hl.A'A*24O2 185 Date Refue/Date Received 2021-03-24CA 03114149 2021-03-24 -21 - [0052] [Table 7] Origin of peptide Amino acid sequence SEQ ID NO. Ovalbumin (OVA) SIINFEKL 196 Murine melanocyte gp100 EGSRNQDWL 197 Human melanocyte gp100 KVPRNQDWL 198 CT26 (colon cancer line) SPSYVYHQF 199 Influenza virus HA IYSTVASSL 200 Influenza virus NP ASNENMDTM 201 Influenza virus PA SSLENFRAYV 202 P-galactosidase DAPIYTNV 203 MuLV (Murine leukemia virus) p15E KSPWFTTL 204 SeV (Sendai virus) FAPGNYPAL 205 MCMV (Murine cytomegalovirus) IE1 YPHFMPTNL 206 LCMV (Lymphocytic choriomeningitis virus) gp33 KAVYNFATM 207 LCMV NP396 FQPQNGQFI 208 LCMV NP118 RPQASGVYM 209 Plasmodium malariae Pb9 SYIPSAEKI 210 HIV P18-I10 RGPGRAFVTI 211 BCG MPT51 GGPHAVYLL 212 Human CEA (Human carcinoembryonic antigen) EAQNTTYL 213 P815 (Mouse-derived antigen-presenting cell) LPYLGWLVF 214 HBsAg (Hepatitis B virus antigen) IPQSLDSWWTSL 215 HSV-1 (Murine herpes simplex virus) gB SSIEFARL 216 HY (Male-specific antigen) Uty WMHHNMDLI 217 EGFP (Enhanced green fluorescent protein) HYLSTQSAL 218 HER2 TYLPTNASL 219 VSV (Vesicular stomatitis virus) NP RGYVYQGL 220 Polyomavirus MT RRLGRTLLL 221

[0053] As the single-chain polynucleotide or polynucleotide derivative constituting a polynucleotide/peptide conjugate, any polynucleotide or polynucleotide derivative having any nucleotide sequence consisting of any numbers of nucleotides can be used without particular limitation, as long as it comprises one or a plurality of (preferably a plurality of) CpG motifs. Specific examples of CpG motifs include AGCGTT, GACGTT, GACGTC, GTCGTT, and the like. The number of CpG motifs contained in the polynucleotide is not particularly limited, but preferably one to six CpG motifs, more preferably two to four CpG motifs, are contained in the polynucleotide. The polynucleotide or polynucleotide derivative is preferably a polydeoxyribonucleotide (DNA) or a phosphorothioate-modified Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -22- DNA derivative comprising two or more CpG motifs, but may be partially composed of an RNA or an RNA derivative. When an RNA or an RNA derivative is contained, the content of one or a plurality of such RNAs or RNA derivatives is preferably not more than 20% (specifically not more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1%).

[0054] The number of nucleotides contained in the polynucleotide or polynucleotide derivative is in the range of preferably from 15 to 40 (specifically 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40), more preferably from 20 to 30 (specifically 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30). Specific examples of preferred polynucleotides or polynucleotide derivatives include those listed in Table 8 below. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -23 - [0055] [Table 8] DNA comprising CpG motifs (5’—>3’) * Phosphodiester bonds are completely substituted with phosphorothioate bonds. SEQ ID NO. "fe ATCGACTCTCGAGCGTTCTC GAGCGTTCTCGAGCGTTCTC CGAOC'GTTCTCGAGCG'TTCTC TC < CGAGCGTICICGAGCGTTCTC GACTCTCGAGCGTTCTCGAGC.GTTCTC gagcgttctcatcgagtctcgagcgttctc ATCGACTCTCGAGCGTTCTCGAGCGTTCTC ATCGACTCTCGAGCOTTCTCATCGACTCTCGAGCQTTCTC CTCAGCGTTCTCAGCGTTCTCAGCOT FCTC TTTAGCGTmTAGCOTTTWAGCOITTTT ttagcgtttagcgtttAGCGTTTAGCGTTT TTAGCG'nTAGCG'TTTAaCGTTTAGCOTTT TCAGCGTTTCAGCGTTTCAGCGTTTC WAOCGTTTTAGCOTTTTAGCQTTTT tCCAT GACGnCCTGATGCT TGACGlicet ICCATGACGTTCCTGATGCT TCCATGACGTrCCTGATGCr TCCArGACGTTCCTGA TGCT tccatgacgttcctgacgtt tgacgttccttccatgacgttcctgacgtt TCCATGACfiTTCC'TaACGm^ ICGTCGTTTTOTCGI 1 1 I'GTCGTT OTCGmCGTCGmTOTCGTrrTGTCG.Tr TCGTCG T T ! 1GrCGTTTCGTCGTT 1 IGICGI 1 1 IGICGt 1 TCMCGTOGTCOTrCGTCXrrTC 1CGTCGTTCGACG11CG1CGTTCGTCGTTC GnCGTCGn'TCGlCGTTCGACG1 1CGTCGTTCGTCGTTC TCGCGACGTTCGCCCGACGTTCGGTA TCGCGACGTTCGCGACG1 1CGCUUGACGTTCGGTA

[0056] Since the polynucleotide is susceptible to degradation by nuclease in the living body, a polynucleotide derivative may be used instead of the polynucleotide with the aim of enhancing stability in the living body. Examples of the polynucleotide derivative include Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -24- those derivatives in which the hydroxyl groups at the 2’ position of a ribonucleotide are completely or partially substituted with fluorine or methoxy groups, those derivatives in which the phosphodiester bonds in a polyribonucleotide (RNA) or a polydeoxyribonucleotide (DNA) are completely or partially substituted with phosphorothioate bonds, and the like. In the case of those derivatives in which the phosphodiester bonds in a polyribonucleotide or a polydeoxyribonucleotide are partially substituted with phosphorothioate bonds, it is preferred that not less than 50% (specifically not less than 50, 60, 70, 80 or 90%) of the phosphodiester bonds should be substituted with phosphorothioate bonds, and it is more preferred that not less than 90% (specifically not less than 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%) of the phosphodiester bonds should be substituted with phosphorothioate bonds. The phosphodiester bonds may be substantially completely substituted with phosphorothioate bonds. The positions of phosphodiester bonds to be substituted with phosphorothioate bonds are not particularly limited. Two or more consecutive phosphodiester bonds may be substituted, or phosphodiester bonds may be substituted so as to ensure that phosphorothioate bonds are not adjacent to each other.

[0057] The polynucleotide or polynucleotide derivative, which is covalently bound to the antigenic peptide via a spacer, can be bound to any of the N-terminus, C-terminus, and side chains of the antigenic peptide, but it is preferred that the polynucleotide or polynucleotide derivative should be bound toward the N-terminus of the antigenic peptide. If an antigenic peptide contains no Cys residue, a peptide modified by adding a Cys residue to the Nterminus of the antigenic peptide can be used. The polynucleotide or polynucleotide derivative and the antigenic peptide are bound together via a spacer, which is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide. As the reactive functional groups used to form bonding between the spacer and the polynucleotide or polynucleotide derivative or between the spacer and the antigenic peptide, any functional groups present in the antigenic peptide and the polynucleotide or polynucleotide derivative can be used as they are, or any groups that can react with a functional group activated by chemical modification to Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -25 - form covalent bonding can be used. It is preferred that an oxygen atom of the hydroxy group at the 5’ end or 3’ end of the polynucleotide or polynucleotide derivative should be bound to the spacer. Also, it is preferred that a sulfur atom of the sulfhydryl group at the side chain of a Cys residue in the antigenic peptide should be bound to the spacer.

[0058] One preferred example of the peptide/polynucleotide conjugate has a structure represented by formula (A) below, in which a region toward the N-terminus of an antigenic peptide is bound via a spacer Sp to a region toward the 3’ end or 5’ end of a polynucleotide or polynucleotide derivative. Formula (A): [Polynucleotide or polynucleotide derivative]-Sp-[Antigenic peptide]

[0059] Examples of the spacer Sp include alkylene group, polyethylene glycol (PEG), and the like. The spacer may comprise a repeating unit having a phosphodiester structure, as represented by the following formula. [0060] [Chern. 4] J n

[0061] In the above formula, X represents an oxygen atom or a sulfur atom (wherein each X may be the same or different), R represents any of (CH2)PO, (CH2)qNH, and (CH2CH2O)m (wherein m, p and q each independently represent a natural number of not more than 10), and n represents a natural number of not more than 10.

[0062] Since such repeating unit do not undergo hydrolysis by nuclease, there occurs no significant decrease in stability in the living body even when X is an oxygen atom. For example, when R is (CFEjs, the size of the repeating unit is nearly equal to that of a ribonucleotide or a deoxyribonucleotide, so that it can be expected that a production cost associated with substitution of part of the polynucleotide or polynucleotide derivative with the spacer can be reduced. Specific examples of the spacer Sp include the following. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -26- [0063] [Chem. 5] o 0“ H S Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -27 - [0064] [Chem. 6] Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 o H o H -P-O^^ b_ Yo — H o "^'S o H 0 O -P-O^^ "'NX^XXSb~ 0 H H o H ^NY°- O O 6“ 0 H H 0 6" H O o H O ^N'^/XSH Date Re^ue/Date Received 2021-03-24CA 03114149 2021-03-24 Date Re^ue/Date Received 2021-03-24CA 03114149 2021-03-24 Date Re^ue/Date Received 2021-03-24CA 03114149 2021-03-24 [0068] [Chem. 10] V O b Z3OH o 6“ Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -32- o o t! n O S~ 5 s o H ° o o S J o H Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -33 - [0070] [Chem. 12] o S" p Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -34-

[0071] Preferred examples of the spacer Sp include those having any of the following structures. [0072] [Chem. 13] -P-O-(CH2)6— O NH-U-O-(CH2)2— O NH~L(CH2)2— ° s— 6- o ° o P-O-(CH2)6—NH-^O-(CH2)2—NH-McH2)2—S— S' O O P-O—(CH2)6—NH— —(CH2)2—-S™ 6' o o -P-O—(CH2)6—NH— (CH2)2—S S‘ O OO -P-O-(CH2)6—NH-^CHsk—NH-^CH^—S— 6' O O P-O-(CH2)6—NH— S' o (CH2)6--NH-lL-(CH2)2—s— O O 0 0 P-O-(CH2)6“NH“^O“(CH2)2—NH-^CHsJs—NH-U—(CH2)2-“S— oO O O 0 -P-O-(CH2)6—NH^O~(CH2)2—NH-^CHsk—NH-U—(CH2)2—s— s-

[0073] Examples of a combination of reactive functional groups used to form bonding between the spacer and the polynucleotide or polynucleotide derivative or between the spacer and the antigenic peptide include not only a combination of reactive functional groups used to form ester bonds, amide bonds, phosphoester bonds, or the like, but also a combination of reactive functional groups used to immobilize a biomolecule on a biochip surface. More Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -35- specific examples thereof are detailed below. [0074] (a) Alkyne and an azide Alkyne and an azide form a 1,2,3-triazole ring through a cycloaddition reaction (Huisgen reaction) as illustrated below. These compounds, which are stable functional groups capable of being introduced into many organic compounds including biomolecules, react with each other rapidly and nearly quantitatively even in a solvent including water, and generate no unnecessary wastes with little side effects; thus, they are widely used predominantly in so-called “click chemistry” reactions in the field of biochemistry. An alkyne derivative and an azido group can be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative using any known method. As for the alkyne derivative, those derivatives having a reactive functional group are easily available, such as propargyl alcohols or propargyl amines. By being reacted directly with a reactive functional group such as carboxyl group or hydroxyl group, or reacted with carbonyldiimidazole or the like, such an alkyne derivative can be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative, through amide bonding, ester bonding, urethane bonding, or other bonding formed by the reaction. The azido group can also be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative using any known method. Additionally, the Huisgen reaction is performed in the presence of a copper catalyst. However, since antigenic peptides, and polynucleotide derivatives in which the phosphodiester bonds are substituted with sulfur-containing functional groups such as phosphorothioate bonds, contain sulfur atoms coordinating to a copper ion, there may occur a deterioration of the catalytic activity of copper. Thus, it is preferred to add an excess amount of copper for the purpose of increasing the rate of reaction. [0075] [Chern. 14] [0076] (b) Maleimide or vinyl sulfone and a thiol group Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -36- Maleimide or vinyl sulfone, which has double bonds adjacent to an electron¬ withdrawing carbonyl or sulfone group, produces a stable thioether derivative at a near¬ neutral pH through an addition reaction (Michael addition reaction) with a thiol group as illustrated below. Since maleimide and vinyl sulfone derivatives containing a suitable spacer are commercially available, it is easy to introduce such a functional group into an antigenic peptide or a polynucleotide or polynucleotide derivative. In the case of introduction of a thiol group into an antigenic peptide, when the antigenic peptide contains cysteine, a thiol group at the side chain of the cysteine residue can be utilized. However, since cysteine is an amino acid with low abundance ratio, a peptide modified by introducing cysteine toward the N-terminus of an antigenic peptide is used. As the polynucleotide or polynucleotide derivative containing a thiol group, a thiolated polynucleotide in which the hydroxyl group at the 5’ end is converted to a thiol group is used. [0077] [Chern. 15] (X: COR' or SO2R') [0078] (c) Thiol group at the side chain of cysteine and thiol group of a thiolated polynucleotide As mentioned above, a thiol group at the side chain of a cysteine residue in an antigenic peptide having cysteine introduced toward the N-terminus thereof is reacted with a thiol group of a thiolated polynucleotide to form a disulfide group. Since the disulfide bonding is cleaved in the presence of a reducing agent, this bonding is inferior in stability over those mentioned in the previous sections. The introduction of a thiol group into a polynucleotide or polynucleotide derivative can be performed using any known method. One specific example of such a method is a reaction of an aminated polynucleotide or polynucleotide derivative with a succinimidyl ester of o>-(2-pyridyldithio)fatty acid as Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -37 - illustrated below. [0079] [Chern. 16] o + h2n-r1 H HS-R2 O

[0080] Inter alia, disulfide bonding formed by combination of a thiol group at the side chain of cysteine with a thiol group of a thiolated polynucleotide is preferred since this bonding is easily cleavable in the living body.

[0081] The polynucleotide/peptide conjugate used as an active component of the immunity¬ inducing agent according to this aspect of the present invention can be in a free form or in the form of a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include salts of alkali metals (e.g., potassium, sodium, lithium), salts of alkali earth metals (e.g., calcium, magnesium), ammonium salts (including tetramethylammonium salt, tetrabutylammonium salt), salts of organic amines (e.g., triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine), and acid adduct salts (including inorganic acid salts such as hydrochloride, hydrobromate, hydroiodide, hydrosulfate, phosphate and nitrate; and organic acid salts such as acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate (mesylate), ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, and gluconate). Further examples of pharmaceutically acceptable salts also include hydrates thereof.

[0082] The pharmaceutical composition according to the second aspect of the present invention (hereinafter also simply abbreviated as “pharmaceutical composition”) comprises the immunity-inducing agent according to the first aspect of this invention. In order to produce the pharmaceutical composition, the peptide/polynucleotide conjugate as an active Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -38- component can be used in combination with any known components (any carriers, excipients and additives acceptable for pharmaceutical purposes) and any known pharmaceutical formulation method. In order to produce the pharmaceutical composition comprising an immunity-inducing agent, the peptide/polynucleotide conjugate as an active component can be used in combination with any known components (any carriers, excipients and additives acceptable for pharmaceutical purposes) and any known pharmaceutical formulation method. Examples of pharmaceutical substances include, but are not limited to, the following: amino acids such as glycine, alanine, glutamine, asparagine, arginine or lysine; antioxidants such as ascorbic acid, sodium sulfate or sodium hydrogen sulfite; buffers such as phosphate buffer, citrate buffer, borate buffer, sodium hydrogen carbonate, or Tris-hydrochloride (Tris-HCl) solution; fillers such as mannitol or glycine; chelators such as ethylenediaminetetraacetic acid (EDTA); complexing agents such as caffeine, polyvinylpyrrolidine, P-cyclodextrin or hydroxypropyl-P-cyclodextrin; bulking agents such as glucose, mannose or dextrin; other carbohydrates such as monosaccharides or disaccharides; colorants; flavorants; diluents; emulsifiers; hydrophilic polymers such as polyvinylpyrrolidine; low-molecular-weight polypeptides; salt-forming counterions; preservatives such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide; solvents such as glycerol, propylene glycol or polyethylene glycol; sugar alcohols such as mannitol or sorbitol; suspending agents; surfactants such as sorbitan esters, polysorbates (e.g., polysorbate 20, polysorbate 80), triton, tromethamine, lecithin or cholesterol; stability enhancers such as sucrose or sorbitol; elasticity enhancers such as sodium chloride, potassium chloride, mannitol or sorbitol; transporting agents; excipients; and/or pharmaceutical aids. Such a pharmaceutical substance is preferably added to a pharmaceutical agent in an amount of from 0.01 to 100 times, especially from 0.1 to 10 times, higher than the weight of the pharmaceutical agent. The preferred compositional profile of a pharmaceutical composition prepared as a pharmaceutical preparation can be determined, as appropriate, by any skilled artisan depending on the disease to be treated, the administration route to be applied, and the like. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -39-

[0083] The pharmaceutical composition is provided in a dosage form suitable for oral or parenteral administration. For example, the pharmaceutical composition is used as an injection, a suppository or the like. Examples of injections include various injection forms such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection and drip infusion. Such injections can be prepared according to known methods. With regard to a method for preparing an injection, the injection can be prepared by, for example, dissolving or suspending the polynucleotide/peptide conjugate of the present invention in a sterile aqueous solvent commonly used for injection. Examples of the aqueous solvent for injection that can be used include distilled water, physiological saline, a buffer such as phosphate buffer, carbonate buffer, Tris buffer or acetate buffer, or the like. The pH of such an aqueous solvent is in the range of from 5 to 10, preferably from 6 to 8. The prepared injection is preferably filled in an appropriate ampule. The injection may be made into a freeze-dried formulation. As for other dosage forms besides injections, the pharmaceutical composition can be provided in a dosage form for transdermal or transmucosal absorption (e.g., liquid spray, ointment, gel, lotion, patch), in a subcutaneous, local, sustained-release dosage form (e.g., suspension containing a nanogel, a biodegradable micro/nano-capsule, etc., temperature-responsive gel), or in the form of a pharmaceutical preparation accompanied with a percutaneous device for skin permeation (e.g,iontophoresis, microneedle), a powder, a tablet, a capsule, a syrup, or an inhalant such as aerosol or dry powder.

[0084] The pharmaceutical composition may further comprise a substance having immunostimulatory activity as an adjuvant. The adjuvant is, but not limited to, a substance that activates innate immunity. The adjuvant is preferably an agonist of an innate immunity receptor. Examples of innate immunity receptor agonists include TLR agonists (e.g., TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR7 agonist, TLR8 agonist, TLR9 agonist), RLR (retinoic acid-inducible gene I (RIG-l)-like receptors) agonists, STING (stimulator of Interferon genes) agonists, NLR (nucleotide-binding oligomerization domain (NOD)-like receptors) agonists, and CLR (C-type lectin receptors) agonists. Examples of TLR agonists Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -40- include lipopeptide, Poly IC RNA, imiquimod, resiquimod, monophosphoryl lipid (MPL), CpG-ODN, and the like. Examples of RLR agonists include pppRNA, Poly IC RNA, and the like. Examples of STING agonists include cGAMP, c-di-AMP, c-di-GMP, and the like. Examples of NLR agonists include iE-DAP, FK565, MDP, murabutide, and the like. Examples of CLR agonists include P-glucan, trehalose-6,6’-dimycolate, and the like. The adjuvant is preferably a TLR agonist, more preferably TLR4 agonist, TLR7 agonist or TLR9 agonist, still more preferably imiquimod, resiquimod, MPL or CpG-ODN. In some embodiments, the adjuvant is imiquimod, MPL or CpG-ODN. The adjuvant is selected as appropriate depending on the type of an antigenic peptide introduced into the peptide/polynucleotide conjugate, or the like. For example, the adjuvant can be CpG DNA or the like, or can be a polynucleotide/p-1,3-glucan complex, as disclosed in International Patent Publication No. WO 2015/118789, which is formed by binding a polynucleotide or polynucleotide derivative containing a partial nucleotide sequence having immunostimulatory activity to a polysaccharide having a P-1,3-glucan backbone via hydrogen bonding, and which has a triple helix structure consisting of one molecular chain of the polynucleotide or polynucleotide derivative and two molecular chains of the polysaccharide having a P-l,3-glucan backbone.

[0085] The pharmaceutical composition can be administered to a human or a warm-blooded animal (e.g., mouse, rat, rabbit, sheep, pig, cow, horse, chicken, cat, dog, monkey) by any of oral and parenteral routes. Examples of parenteral routes include subcutaneous, intracutaneous and intramuscular injections, intraperitoneal administration, drip infusion, and spray into nasal mucosa or pharyngeal region.

[0086] The dose of the peptide/polynucleotide conjugate serving as an active component of the pharmaceutical composition differs according to activity, the disease to be treated, the type, body weight, sex and age of an animal to be medicated, the severity of a disease, administration method, and/or the like. As an example, in the case of medication of an adult human with a body weight of 60 kg, the daily dose for oral administration is generally in the range of from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -41 - preferably from about 1.0 to about 20 mg, and the daily dose for parenteral administration is generally in the range of from about 0.01 to about 30 mg, preferably from about 0.1 to about 20 mg, more preferably from about 0.1 to about 10 mg. When the pharmaceutical composition is administered to other animals, the dose to be used for such animals is calculated by converting the aforementioned dose into a dose per unit body weight and multiplying the dose per unit body weight by the body weight of an animal to be medicated.

[0087] By administering the pharmaceutical composition according to this aspect of the present invention to a patient with a pathogenic infection or a cancer, or a subject predisposed to suffering from a cancer or a pathogenic infection, cytotoxic T lymphocytes (CTLs) present in the medicated patient or subject are activated in an antigen-specific manner to induce antigen-specific antibody production, or namely to induce a protective immune response of a warm-blooded animal (preferably a human), thereby enabling prevention or treatment of the infection or cancer. In other words, the pharmaceutical composition according to this aspect of the invention is useful as a vaccine for the prevention or treatment of diseases such as infections or cancers as mentioned above. In this invention, the terms “tumor(s)” and “cancer(s)” are exchangeably used. Also, in this invention, tumors, malignant tumors, cancers, malignant neoplasms, carcinomas, sarcomas and the like may be collectively referred to as “tumors” or “cancers”. Further, the terms “tumor(s)” and “cancer(s)” may in some cases include pathological conditions classified as pre-cancer stages, such as myelodysplastic syndromes.

[0088] The types of tumors to be treated are not particularly limited as long as they are tumors proved to be susceptible to the pharmaceutical composition of the present invention. Examples of tumors to be treated include breast cancer, colon cancer, prostate cancer, lung cancer (including small-cell lung cancer, non-small-cell lung cancer, etc.), stomach cancer, ovarian cancer, cervical cancer, endometrial cancer, corpus uteri cancer, kidney cancer, hepatocellular cancer, thyroid cancer, esophageal cancer, osteosarcoma, skin cancer (including melanoma, etc.), glioblastoma, neuroblastoma, ovarian cancer, head and neck cancer, testicular tumor, bowel cancer, blood cancer (including leukemia, malignant Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -42- lymphoma, multiple myeloma, etc.), retinoblastoma, pancreatic cancer, and the like.

[0089] The pharmaceutical composition according to this aspect of the present invention may be used in combination with other antitumor agents. Examples of other antitumor agents include antitumor antibiotics, antitumor plant extracts, BRMs (biological response modifiers), hormones, vitamins, antitumor antibodies, molecular targeted drugs, alkylating agents, metabolic antagonists, other antitumor agents, and the like.

[0090] More specifically, examples of alkylating agents include alkylating agents such as nitrogen mustard, nitrogen mustard N-oxide, bendamustine or chlorambucil; aziridine-based alkylating agents such as carboquone or thiotepa; epoxide-based alkylating agents such as dibromomannitol or dibromodulcitol; nitrosourea-based alkylating agents such as carmustine, lomustine, semustine, nimustine hydrochloride, streptozocin, chlorozotocin or ranimustine; other alkylating agents such as busulfan, improsulfan tosilate, temozolomide or dacarbazine, and the like.

[0091] Examples of metabolic antagonists include purine metabolic antagonists such as 6-mercaptopurine, 6-thioguanine or thioinosine; pyrimidine metabolic antagonists such as fluorouracil, tegafur, tegafur-uracil, carmofur, doxifluridine, broxuridine, cytarabine or enocitabine; folate metabolic antagonists such as methotrexate or trimetrexate, and the like.

[0092] Examples of antitumor antibiotics include mitomycin C, bleomycin, peplomycin, daunorubicin, aclarbicin, doxorubicin, idarubicin, pirarubicin, THP-adriamycin, 4’-epi-doxorubicin or epirubicin, chromomycin A3 or actinomycin D, and the like.

[0093] Examples of antitumor plant extracts and derivatives thereof include vinca alkaloids such as vindesine, vincristine or vinblastine; taxanes such as paclitaxel, docetaxel or cabazitaxel; or epipodophyllotoxins such as etoposide or teniposide, and the like.

[0094] Examples of BRMs include tumor necrosis factors or indomethacin, and the like.

[0095] Examples of hormones include hydrocortisone, dexamethasone, methylprednisolone, prednisolone, prasterone, betamethasone, triamcinolone, oxymetholone, nandrolone, metenolone, fosfestrol, ethinylestradiol, chlormadinone, mepitiostane or medroxyprogesterone, and the like. Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -43 -

[0096] Examples of vitamins include vitamin C or vitamin A, and the like.

[0097] Examples of antitumor antibodies or molecular targeted drugs include trastuzumab, rituximab, cetuximab, panitumumab, nimotuzumab, denosumab, bevacizumab, infliximab, ipilimumab, nivolumab, pembrolizumab, avelumab, pidilizumab, atezolizumab, ramucirumab, imatinib mesylate, dasatinib, sunitinib, lapatinib, dabrafenib, trametinib, cobimetinib, pazopanib, palbociclib, panobinostat, sorafenib, crizotinib, vemurafenib, kizaruchinib, bortezomib, carfilzomib, ixazomib, midostaurin, gilteritinib, and the like.

[0098] Examples of other antitumor agents include cisplatin, carboplatin, oxaliplatin, tamoxifen, letrozole, anastrozole, exemestane, toremifene citrate, fulvestrant, bicalutamide, flutamide, mitotane, leuprorelin, goserelin acetate, camptothecin, ifosfamide, cyclophosphamide, melphalan, L-asparaginase, aceglatone, schizophyllan, picibanil, procarbazine, pipobroman, neocarzinostatin, hydroxyurea, ubenimex, thalidomide, lenalidomide, pomalidomide, eribulin, tretinoin or krestin, and the like.

[0099] Examples of infections to be treated include infections with pathogens such as viruses, fungi or bacteria. Examples of viruses include influenza virus, hepatitis virus, human immunodeficiency virus (HIV), RS virus, rubella virus, measles virus, epidemic parotitis virus, herpesvirus, poliovirus, rotavirus, Japanese encephalitis virus, varicella virus, adenovirus, rabies virus, yellow fever virus, and the like. Examples of bacteria include Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, Hemophilus influenza, Mycobacterium tuberculosis, Streptococcus pneumoniae, Helicobacter pylori, Bacillus anthracis, Salmonella typhosa, Neisseria meningitidis, Bacillus dysenteriae, Vibrio cholerae, and the like. Examples of fungi include fungi of the genus Candida,fungi of the genus Histoplasma, fungi of the genus Cryptococcus, fungi of the genus Aspergillus, and the like. The pharmaceutical composition of the present invention may be used in combination with existing therapeutic agents for such infections.

[0100] Administration of the pharmaceutical composition of this aspect of the present invention in combination with an adjuvant or other drugs means ingestion of both of the drugs into the body of a medicated subject within a certain period of time. A single Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -44- preparation incorporating both of the drugs may be administered, or both of the drugs may be formulated into separate preparations and administered separately. When both of the drugs are formulated into separate preparations, the timings of administration of the separate preparations are not particularly limited, and they may be administered simultaneously or may be sequentially administered at intervals of times or days. When separate preparations are administered at different times or on different days, the order of their administration is not particularly limited. Since separate preparations are generally administered according to their respective administration methods, the numbers of doses of these preparations may be the same or different. Also, when both of the drugs are formulated into separate preparations, the separate preparations may be administered by the same administration method (via the same administration route) or by different administration methods (via different administration routes). Further, both of the drugs are not necessarily present simultaneously in the body, and it is only necessary that both of the drugs should be ingested into the body within a certain period of time (e.g., for one month, preferably for one week, more preferably for a few days, still more preferably for one day). The active component of one preparation may be eliminated from the body at the time of administration of the other preparation. EXAMPLES

[0101] Next, the following describes working examples conducted to confirm the actions and effects of the present invention. As referred to in the following examples, the term “CpG DNA(S)” refers to a DNA derivative (an example of polynucleotide derivative) which has a nucleotide sequence comprising a CpG motif(s) and in which phosphodiester bonds are substituted with phosphorothioate bonds. In the chemical structural formulas shown in the following examples, the nucleotide sequences of polynucleotide derivatives are written in single letter codes with the 5’ end to the left (and the 3’ end to the right), and the amino acid sequences of peptides, except for cysteine at the N-terminus, are written in three letter codes with the N-terminus to the left (and the C-terminus to the right). In the polynucleotide derivatives written in single letter codes, all phosphodiester bonds are substituted with Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -45 - phosphorothioate bonds, and their termini end with an oxygen atom at the 5’- or 3’-hydroxy group of the terminal nucleoside when coupled to a spacer, or end with the entire 5’- or 3’-hydroxy group (including a hydrogen atom) of the terminal nucleoside when not coupled to a spacer. Further, in the following examples, the CpG DNA(S)-peptide conjugate was prepared in the form of a salt having triethylamine and acetic acid added thereto.

[0102] Example 1: Preparation of a CpG DNA(S)-peptide conjugate One mol of amino group-modified CpG DNA(S) synthesized by a given method known in the art (a CpG DNA(S) derivative having introduced at its 5’ end an amino group with a structure represented by the following formula; nucleotide sequence: ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC (SEQ ID NO: 229; hereinafter abbreviated as “CpG40(S)”); all phosphodiester bonds were substituted with phosphorothioate bonds) was mixed with 30 mol of succinimidyl 6-[3’-(2-pyridyldithio)-propionamido]hexanoate (LC-PDP) in a phosphate buffer (pH 8.0). After being left to stand at 40°C for 3 hours, SPDP-modified CpG DNA(S) was purified using a NAP-5 column. [0103] [Chern. 17]

[0104] Hereinafter, the structure represented by the following formula is abbreviated as “ssH amino linker”. [0105] [Chern. 18]

[0106] A peptide (amino acid sequence: CSIINFEKL (SEQ ID NO: 250; hereinafter abbreviated as “OVApep9”)) having cysteine added toward the N-terminus of an ovalbumin Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -46- (OVA)-derived antigenic peptide (257th to 264th amino acids (amino acid sequence: SIINFEKL (SEQ ID NO:196))) was mixed at a ratio of 25 mol to 1 mol of the SPDPmodified CpG DNA(S) in an aqueous solution of 30% N,N-dimethylformamide (DMF). After being left to stand at 40°C for 3 hours, the mixture was fractionated by HPLC to obtain a CpG DNA(S)-peptide conjugate. HPLC was performed under the following gradient conditions using 0.1 M triethylammonium acetate (TEAA; pH 7.0) and acetonitrile as solvents A and B, respectively, and the column ZORBAX Eclipse Plus Cl8. 0 min. A: 90% B: 10% to 25 min. A: 70% B: 30% to 30 min. A: 0% B: 100%

[0107] During the process of the HPLC fractionation of the solution obtained after the reaction of SPDP-modified CpG DNA(S) with the OVA-derived peptide, detection was performed by monitoring the absorption at 260 nm for dA40(S). ft was observed that the elution time of the peak of the fractionated CpG DNA(S)-peptide conjugate was delayed as compared to that of SPDP-modified CpG DNA(S). This is considered to be because the elution time became later since SPDP-modified CpG DNA(S) was bound to the hydrophobic peptide. Further, in the chromatogram obtained from the fractionation, no peak for unreacted SPDP-modified CpG DNA(S) was observed, and only the peak for the CpG DNA(S)-peptide conjugate was detected — this fact confirmed that the CpG DNA(S)-peptide conjugate of interest (CpG40(S)-OVApep9 conjugate; see below for its structural formula) was obtained in high purity. [0108] [Chern. 19] CpG40(S} (SEQ ID NO:229)

[0109] Example 2: Evaluation of induction of cytotoxic T lymphocytes by CpG DNA(S)-peptide conjugate Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -47- The CpG DNA(S)-peptide conjugate was intracutaneously administered as an antigen to mice (C57BL/6 mice (J, 7 weeks old)) (once at 20 ng per mouse). After one week of administration, splenocytes were isolated from those mice of the same strain not receiving administration, and divided into two groups. To one group, an ovalbumin (egg albumin, OVA)-derived antigenic peptide (peptide sequence: SIINFEKL (SEQ ID NO: 196)) was added, and the mixture was left to stand for 90 minutes to prepare antigen-retaining splenocytes. The other group of splenocytes not receiving addition of the peptide was regarded as non-antigen-retaining splenocytes. Both of the antigen-retaining splenocytes and the non-antigen-retaining splenocytes were fluorescently modified with 5,6-carboxyfluorescein succinimidyl ester (CFSE). During this process, the concentration of CFSE was varied such that the fluorescence intensity of the antigen-retaining splenocytes (CFSE: 5 pM) was higher than that of the non-antigen-retaining splenocytes (CFSE: 0.5 pM). The same numbers of the antigen-retaining and non-antigen-retaining splenocytes were mixed together, and administered via tail vain to the mice administered the CpG DNA(S)-peptide conjugate as an antigen, after one week of administration. The dose of the CpG DNA(S)-peptide conjugate was 20 ng per mouse in terms of peptide (250 ng in terms of CpG40(S)).

[0110] After the lapse of 24 hours from the tail vein administration, splenocytes were isolated from the mice, and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigenretaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes. The results of the flow cytometric analysis are shown in FIG. 1 (FIG. 1(b)). For comparison’s sake, the results of the flow cytometric analysis conducted for the control groups under the same conditions are also shown in FIG. 1; as the control groups, other mice were either administered PBS (phosphate-buffered saline) (FIG. 1(a)) or separately administered the antigenic peptide and CpG DNA(S) (FIG. 1(c)), instead of the CpG DNA(S)-peptide conjugate.

[0111] As shown in FIG. 1(a), the splenocytes collected from the mice administered PBS Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -48 - contained the same numbers of antigen-retaining and non-antigen-retaining splenocytes. However, as shown in FIG. 1(b), about 95% of antigen-retaining splenocytes disappeared from the splenocytes collected from the mice administered the CpG DNA(S)-peptide conjugate. This revealed that administration of the CpG DNA(S)-peptide conjugate resulted in induction of a peptide antigen-specific immune response. Also, by comparison with FIG. 1(c), it was found that the effect of administration of the CpG DNA(S)-peptide conjugate was higher than that of separate administration of the antigenic peptide and CpG DNA(S).

[0112] Example 3: Dependence on the dose of a CpG DNA(S)-peptide conjugate Mice were immunized with varied doses of the CpG DNA(S)-peptide conjugate. Then, as in Example 2, the same numbers of antigen-retaining and non-antigen-retaining splenocytes were mixed together, and administered via tail vain to the mice administered the CpG DNA(S)-peptide conjugate. Thereafter, splenocytes were isolated from the mice, and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes.

[0113] The results of the flow cytometric analysis are shown in FIG. 2. It was found that as the dose of the CpG DNA(S)-peptide conjugate was decreased to less than 20 ng in terms of peptide, the effect of the conjugate diminished gradually. In general, peptide immunization requires administration of the peptide at a dose of several micrograms. However, by the use of the CpG DNA(S)-peptide conjugate prepared in Example 1, the peptide dose was successfully reduced to a hundredth to a thousandth.

[0114] Example 4: Dependence on the nucleotide length and nucleotide sequence of CpG DNA(S) contained in a CpG DNA(S)-peptide conjugate Different CpG DNA(S)-peptide conjugates were prepared by the same procedure as in Example 1, except that the 40-nucleotide-long CpG DNA(S) derivative (nucleotide sequence: ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC (SEQ ID NO: 229; hereinafter abbreviated as “CpG40(S)”)), which was used to prepare a CpG DNA(S)-peptide conjugate in Example 1, was replaced with any of the following CpG Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -49- DNA(S) derivatives: 3O-nucleotide-long CpG DNA(S) derivatives (nucleotide sequence: GAGCGTTCTCATCGACTCTCGAGCGTTCTC (SEQ ID NO: 227; hereinafter abbreviated as “CpG30(S)a”), and nucleotide sequence: ATCGACTCTCGAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 228; hereinafter abbreviated as “CpG30(S)b”)); a 24-nucleotide-long CpG DNA(S) derivative (nucleotide sequence: TCTCGAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 225; hereinafter abbreviated as “CpG24(S)”)); and 20-nucleotide-long CpG DNA(S) derivatives (nucleotide sequence: ATCGACTCTCGAGCGTTCTC (SEQ ID NO: 222; hereinafter abbreviated as “CpG20(S)a”, and nucleotide sequence: GAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 223; hereinafter abbreviated as “CpG20(S)b”)) (see below for their structural formulas) (as for the structural formulas and nucleotide sequences of these derivatives, see the structural formulas and Table 9 shown below; the nucleotide sequences indicated in boldface with underline in Table 9 are CpG motifs; all phosphodiester bonds were substituted with phosphorothioate bonds). [0115] [Table 9] Abbreviated name Nucleotide sequence SEQ ID NO. CpG40(S} ATCGACTCTCGAfiSSI^ 229 CpG30(S)a GAGCGTTCTCATCGACTCTCGABCQITCTC 227 CpG30(S)b ATCGACTCTCGAQCQWCTCGAGCflnCTC ; SS CpG24(S) TCTOGAGCGTTCTCGAGCOT 226 CpG20(3> ATCGACTCTCGAGCGTTCTC 222 CpGM(S)b 'GAOCO.TTCTC'GAGCGTTCTC ’ [0116] [Chern. 20] C^2D(8)Si (SEQ ID NO:222) , ATCGACTCTCGAGCGTTCTC V p -S^^'SerlleiteAsnFI^^ 6“ o H I NHa OVApep? (SEQ ID NQ:250) Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -50- OVApepU (SEQ ID NQ:250) [0117] [Chem. 21] CpG20<S)b (SEQ ID NO:223) GAGCGTTCTCGAGCGI ICTC [0118] [Chem. 22] earn(SEQ ID NO:225) /TCraMOC^WCTCGAGCGTTCTC : O.^nL< S-S O Q O H O NH;t OVApcp9 (SEQ ID NQ:250) SerlleilaAsrf’heGMLysLeu OVApepQ (SEQ ID NQ:250) [0119] [Chem. 23] CpG30(S> (SEQ ID NO:227) / GAGCQTTCTCAICGACTCTCGAGCGTTCrC [0120] [Chem. 24] CpG30(S)b (SEQ ID NO:228) •la OVApppO (SEQ ID NQ:250) r AICGACTCTCGAGCGr 1C1CGAGCGTTCTC

[0121] Mice were immunized with the different CpG DNA(S)-peptide conjugates comprising different nucleotide lengths of CpG DNA(S) (20 ng per mouse in terms of peptide), and then, as in Example 2, administered a mixture of antigen-retaining and nonantigen-retaining splenocytes by tail vein injection and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen¬ retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes.

[0122] The results of the flow cytometric analysis are shown in FIGs. 3 and 4. It was found that even in the case of CpG DNA(S) shorten to 30 nucleotides, antigen-retaining splenocytes completely disappeared. With regard to CpG DNA(S) shorten to 20 nucleotides, no decrease in the number of antigen-retaining splenocytes was observed in the Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -51 - case of CpG DNA(S) containing only a single CpG motif, whereas a decrease in the number of antigen-retaining splenocytes was observed in the case of CpG DNA(S) containing two CpG motifs, which indicates that the activity of peptide-specific cytotoxic T lymphocytes was induced.

[0123] Example 5: Dependence on the amino acid length of a peptide contained in a CpG DNA(S)-peptide conjugate Different CpG DNA(S)-peptide conjugates were prepared using a 18-amino acidlong peptide (amino acid sequence: CEVSGLEQLESIINFEKL (SEQ ID NO: 251; hereinafter abbreviated as “OVApepl8”)) or a 27-amino acid-long peptide (amino acid sequence: CMSMLVLLPDEVSGLEQLESIINFEKL (SEQ ID NO: 252; hereinafter abbreviated as “OVApep27”)), which were generated by extending the antigenic peptide used in the CpG DNA(S)-peptide conjugate of Example 1 in a direction toward the N-terminus (see below for the structural formulas of the two conjugates). Mice were immunized with the different CpG DNA(S)-peptide conjugates (20 ng per mouse in terms of peptide), and then, as in Example 2, administered a mixture of antigen-retaining and non-antigen-retaining splenocytes by tail vein injection and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and nonantigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes. [0124] [Chern. 25] CpG40(S) (SEQ ID NO: 229) ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -52- [0125] [Chem. 26] CpG40(S) (SEQ ID NO: 229)

[0126] The results of the flow cytometric analysis are shown in FIG. 5. It was observed that the activity of peptide-specific cytotoxic T lymphocytes tends to decrease when the length of the antigenic peptide is extended to 18 or 27 amino acids.

[0127] Example 6: Dependence on the spacer structure and the conjugation site of peptide in a CpG DNA(S)-peptide conjugate Evaluation of induced cytotoxic T lymphocyte activity was conducted by the same procedure as in Example 2 by using three different CpG DNA(S)-peptide conjugates as detailed below: a CpG DNA(S)-peptide conjugate which was prepared using an amino linker with the structure shown below (hereinafter abbreviated as “C6 amino linker”) instead of the ssH amino linker used to prepare the CpG DNA(S)-peptide conjugate of Example 1 (hereinafter referred to as “Compound (I)”); a CpG DNA(S)-peptide conjugate in which a PEGylated Cl8 spacer was inserted between CpG DNA(S) and the ssH amino linker; and a CpG DNA(S)-peptide conjugate in which an antigenic peptide was covalently bound to the 3’ end, not to the 5’ end, of CpG DNA(S) via the same spacer structure as used in Compound (I). As a result, it was observed that immunization with any of these conjugates resulted in induction of potent peptide-specific cytotoxic T lymphocyte activity to comparable levels to immunization with the CpG DNA(S)-peptide conjugate prepared in Example 1. [0128] [Chem. 27] o Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -53 - [0129] [Chem. 28] CpG40(S) (SEQ ID NO: 229) r ATCGACTCTCGAGGGTTCTCATCGACTCTCGAGCGTTCTC Irt' I O ©A 14 °ji (I) w P S Se'^lteAsnPbeGluLyaLai w H N"2 OVApepS (SEQ ID NO: 250) "^v O'"''-' [0130] [Chem. 29] CpG4O(S) (SEQ ID NO: 229) Y^SsrtWteAtnRwGMytltu WHi 0WW> (SEQ ID NO: 250) -S SerltelteAsnPheGIt^Uu C*^ (SEQ ID NO: 250) [0131] [Chem. 30] CpG40(S) (SEQ ID NO: 229) ATCGACTCTCGAGCG TTCTCATCGACTCrCGAGCGTTCTC

[0132] Example 7: Evaluation of the amount of antigen presented on peritoneal macrophages Peritoneal macrophages collected from mice were placed in 48-well plates (1.5xl05 cells/well). Different CpG DNA(S)-peptide conjugates prepared using different amino acid lengths of antigenic peptides (OVApep9, OVApepl8, OVApep27) and different nucleotide lengths of CpG DNA(S) (CpG40(S), CpG30(S)a, CpG30(S)b, CpG20(S)a) were added to the wells at a concentration of 2 pg/mL in terms of peptide, followed by culturing for 24 hours. After the culturing, an antibody specific for the OVApep8-MHC molecular complex (fluorescently labeled with phycoerythrin (PE); hereinafter abbreviated as “PE labelled H-2Kb/FIINFEKL”) was added, and antibody-bound peritoneal macrophages were quantified Date Regue/Date Received 2021-03-24CA 03114149 2021-03-24 -54- by flow cytometry to evaluate the amount of antigen presented.

[0133] The results of the flow cytometric analysis are shown in FIGs. 6 and 7. The results demonstrated that the nucleotide length of CpG DNA(S) has little effect on the amount of antigen presented, and that the amount of antigen presented tends to decrease as the antigenic peptide is extended to a length of 18 or 27 amino acids. Also, from the result obtained in FIG. 7 for “CpG40(S)-PEG-OVApep9”, which is a CpG40(S)-OVApep9 conjugate having a polyoxyethylene group inserted into a spacer, it was observed that the polyoxyethylene group inserted into the spacer has little effect on the amount of antigen presented. Date Regue/Date Received 2021-03-24

Claims (15)

1. - 55 - CLAIMS 1. An immunity-inducing agent comprising a polynucleotide/peptide conjugate in which a polynucleotide portion of the polynucleotide/peptide conjugate comprising a single-chain polynucleotide or polynucleotide derivative thereof comprising a CpG motif, and a peptide portion of the polynucleotide/peptide conjugate comprising an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif and covalently bound at the other end thereof to the antigenic peptide, wherein the spacer comprises a repeating unit represented by the following formula: wherein X represents an oxygen atom or a sulfur atom, wherein each X may be the same or different, R represents any of (CH2)pO, (CH2)qNH, and (CH2CH2O)m, wherein m, p and q each independently represent a natural number from 1 to 10, and n represents a natural number of from 1 to 10, and wherein the polynucleotide derivative is a polynucleotide in which i) the hydroxyl groups at the 2’ position of a ribonucleotide are completely or partially substituted with fluorine or methoxy groups or ii) the phosphodiester bonds in a polyribonucleotide (RNA) or a polydeoxyribonucleotide (DNA) are completely or partially substituted with CA 3114149 Date reçue / Received date 2024-08-07- 56 - phosphorothioate bonds.
2. 2. The immunity-inducing agent according to claim 1, wherein the antigenic peptide has an amino acid length of from 5 to 30.
3. 3. The immunity-inducing agent according to claim 1 or 2, wherein the antigenic peptide has an amino acid length of fom 8 to 11.
4. 4. The immunity-inducing agent according to any one of claims 1 to 3, wherein the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif is a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs.
5. 5. The immunity-inducing agent according to any one of claims 1 to 4, wherein the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif has a nucleotide length of from 15 to 40.
6. 6. The immunity-inducing agent according to any one of claims 1 to 5, wherein the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif has a nucleotide length of from 20 to 30.
7. 7. The immunity-inducing agent according to any one of claims 1 to 6, wherein the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif is a polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds.
8. 8. The immunity-inducing agent according to claim 7, wherein, in the polynucleotide CA 3114149 Date reçue / Received date 2024-08-07- 57 - derivative at least 50% of the phosphodiester bonds are substituted with phosphorothioate bonds.
9. 9. The immunity-inducing agent according to claim 7 or 8, wherein, in the polynucleotide derivative at least 90% of the phosphodiester bonds are substituted with phosphorothioate bonds.
10. 10. The immunity-inducing agent according to any one of claims 1 to 9, wherein one or both of the covalent bond between the spacer and the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif, and the covalent bond between the spacer and the antigenic peptide are a covalent bond(s) that is(are) cleavable in biological environment.
11. 11. The immunity-inducing agent according to claim 10, wherein the antigenic peptide which constitutes the polynucleotide/peptide conjugate, and the spacer bound to the single-chain polynucleotide or polynucleotide derivative thereof comprising the CpG motif are bound together via a disulfide bond produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer.
12. 12. The immunity-inducing agent according to any one of claims 1 to 11, wherein the spacer has a structure represented by any one of the following formulas: CA 3114149 Date reçue / Received date 2024-08-07- 58 - and .
13. 13. The immunity-inducing agent according to any one of claims 1 to 12, further comprising a substance having immunostimulatory activity as an adjuvant.
14. 14. A pharmaceutical composition comprising the immunity-inducing agent according to any one of claims 1 to 13, and a pharmaceutically acceptable excipient or carrier.
15. 15. A pharmaceutical composition for treating tumor, comprising the immunityCA 3114149 Date reçue / Received date 2024-08-07- 59 - inducing agent according to any one of claims 1 to 13, and a pharmaceutically acceptable excipient or carrier. CA 3114149 Date reçue / Received date 2024-08-07